ReviewPostgraduate medical journal2006
Chronic hepatitis B in hepatocarcinogenesis.
Review in Postgraduate medical journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 70 citations in OpenAlex.
- Trial
- Potential role of epidermal growth factor receptors (EGFR) signaling in the pathogenesis and management of hepatocellular carcinoma.BioImpacts : BI · 2025Review
- HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis.Oncogene · 2020Article
- ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications.Experimental & molecular medicine · 2018Review
- Anti-HBV Activities of Three Compounds Extracted and Purified from Herpetospermum Seeds.Molecules (Basel, Switzerland) · 2016Article
- Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma.World journal of gastroenterology · 2016Article
- Association of PTEN gene polymorphisms with liver cancer risk.International journal of clinical and experimental pathology · 2015Article
- Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro.Journal of Zhejiang University. Science. B · 2014Article
- HBx Gene Mutations in Hepatitis B Virus and Hepatocellular Carcinoma.Gastroenterology research · 2014Review
- Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer.Oncogene · 2012Article
- Molecular hepatic carcinogenesis: impact of inflammation.Digestive diseases (Basel, Switzerland) · 2012Review
- Ethanol Extract from Ampelopsis sinica Root Exerts Anti-Hepatitis B Virus Activity via Inhibition of p53 Pathway In Vitro.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2010Article
- In vitro anti-hepatitis B virus effect of Hypericum perforatum L.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2010Article
- Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues.Journal of experimental & clinical cancer research : CR · 2009Article
- Recent advancements for the evaluation of anti-viral activities of natural products.New biotechnology · 2009Review
- Mouse models in liver cancer research: a review of current literature.World journal of gastroenterology · 2008Review
- Viruses associated with human cancer.Biochimica et biophysica acta · 2008Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and has a wide geographical variation. Eighty per cent of HCC is attributed to hepatitis B virus (HBV). The predominant carcinogenic mechanism of HBV associated HCC is through the process of liver cirrhosis, but direct oncogenic effects of HBV may also contribute. Prevention of HBV infections as well as effective treatment of chronic hepatitis B is still needed for the global control of HBV associated HCC. Continued investigation of the mechanisms of hepatocarcinogenesis will refine our current understanding of the molecular and cellular basis for neoplastic transformation in the liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.